Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARα and CAR/PXR

Toxicology

Volumn 293, Issue 1-3, 2012, Pages 16-29

  Elcombe, Clifford R ^a   Elcombe, Barbara M ^a   Foster, John R ^b   Chang, Shu Ching ^c   Ehresman, David J ^c   Butenhoff, John L ^c  

^a CXR Biosciences Ltd   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c 3M COMPANY   (United States)

Author keywords

CAR; Hepatomegaly; PFOS; Potassium perfluorooctanesulfonate; PPAR ; PXR

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2B1; CYTOCHROME P450 2E1; CYTOCHROME P450 3A1; CYTOCHROME P450 4A1; DNA; GLUCOSE; LIPID; LIVER PROTEIN; PERFLUOROOCTANESULFONATE POTASSIUM; PERFLUOROOCTANESULFONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHENOBARBITAL; PREGNANE X RECEPTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL PROLIFERATION; CELL STIMULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; HEPATOCELLULAR HYPERTROPHY; HEPATOMEGALY; HISTOPATHOLOGY; LIPID BLOOD LEVEL; LIVER ADENOMA; LIVER CELL; LIVER HYPERTROPHY; LIVER WEIGHT; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; THYROID FOLLICLE CELL; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ADENOMA, LIVER CELL; ALKANESULFONIC ACIDS; ANIMALS; APOPTOSIS; CARCINOGENS; CELL PROLIFERATION; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; FLUOROCARBONS; HEPATOMEGALY; LIVER; LIVER NEOPLASMS; MALE; NEOPLASM PROTEINS; PPAR ALPHA; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; THYROID GLAND; TOXICITY TESTS, SUBACUTE;

RATTUS;

EID: 84862777680     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2011.12.014     Document Type: Article

References (79)

1. Alexander B.H., Olsen G.W., Burris J.M., Mandel J.H., Mandel J.S. Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. Occup. Environ. Med. 2003, 60:722-729.
2. Benskin J.P., De Silva A.O., Martin L.J., Arsenault G., McCrindle R., Riddell N., Mabury S.A., Martin J.W. Disposition of perfluorinated acid isomers in Sprague-Dawley rats; part 1: single dose. Environ. Toxicol. Chem. 2009, 28:542-554.
3. Bentley P., Calder I., Elcombe C., Grasso P., Stringer D., Wiegand H.J. Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem. Toxicol. 1993, 31:857-907.
4. Bijland S., Rensen P.C.N., Pieterman E.J., Maas A.C.E., van der Hoorn J.W., van Erk M.J., Havekes L.M., van Dijk K.W., Chang S., Ehresman D.J., Butenhoff J.L., Princen H.M.G. Perfluoroalkyl sulfonates cause chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden.CETP mice. Toxicol. Sci. 2011, 123:290-303.
5. Bjork J.A., Wallace K.B. Structure-activity relationships and human relevance for perfluoroalkyl acid-induced transcriptional activation of peroxisome proliferation in liver cell cultures. Toxicol. Sci. 2009, 111:89-99.
6. Bjork J.A., Butenhoff J.L., Wallace K.B. Multiplicity of nuclear receptor activation by PFOA and PFOS in primary human and rodent hepatocytes. Toxicology 2011, 288:8-17.
7. Bronfman M., Inestrosa N.C., Leighton F. Fatty acid oxidation by human liver peroxisomes. Biochem. Biophys. Res. Commun. 1979, 88:1030-1036.
8. Burton K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J. 1956, 62:315-323.
9. Butenhoff J.L., Chang S.C., Olsen G.W., Thomford P.J. Chronic dietary toxicity and carcinogenicity study with potassium perfluorooctanesulfoante in Sprague-Dawley rats. Toxicology 2012, 293:1-15.
10. Capen C.C. Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. Toxicol. Pathol. 1997, 25:39-48.
11. Chang S.C., Thibodeaux J.R., Eastvold M.L., Ehresman D.J., Bjork J.A., Froehlich J.W., Lau C.S., Singh R.J., Wallace K.B., Butenhoff J.L. Negative bias from analog methods used in the analysis of free thyroxine in rat serum containing perfluorooctanesulfonate (PFOS). Toxicology 2007, 234:21-33.
12. Chang S.C., Thibodeaux J.R., Eastvold M.L., Ehresman D.J., Bjork J.A., Froehlich J.W., Lau C., Singh R.J., Wallace K.B., Butenhoff J.L. Thyroid hormone status and pituitary function in adult rats given oral doses of perfluorooctanesulfonate (PFOS). Toxicology 2008, 243:330-339.
13. Chang, S.C., Noker, P.E., Gorman, G.S., Gibson, S.J., Hart, J.A., Ehresman, D.J., Butenhoff, J.L., in press. Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, and monkeys. Reprod. Toxicol., doi:10.1016/j.reprotox.2011.07.002.
14. Cheung C., Akiyama T.E., Ward J.M., Nicol C.J., Feigenbaum L., Vinson C., Gonzalez F.J. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res. 2004, 64:3849-3854.
15. Cohen S.M., Klaunig J., Meek M.E., Hill R.N., Pastoor T., Lehman-McKeeman L., Bucher J., Longfellow D.G., Seed J., Dellarco V., Fenner-Crisp P., Patton D. Evaluating the human relevance of chemically induced animal tumors. Toxicol. Sci. 2004, 78:181-186.
16. Craft E.S., DeVito M.J., Crofton K.M. Comparative responsiveness of hypothyroxinemia and hepatic enzyme induction in Long-Evans rats versus C57BL/6J mice exposed to TCDD-like and phenobarbital-like polychlorinated biphenyl congeners. Toxicol. Sci. 2002, 68:372-380.
17. Curran P.G., DeGroot L.J. The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland. Endocr. Rev. 1991, 12:135-150.
18. Curran I., Hierlihy S.L., Liston V., Pantazopoulos P., Nunnikhoven A., Tittlemier S., Barker M., Trick K., Bondy G. Altered fatty acid homeostasis and related toxicologic sequelae in rats exposed to dietary potassium perfluorooctanesulfonate (PFOS). J. Toxicol. Environ. Health A 2008, 71:1526-1541.
19. Doull J., Cattley R., Elcombe C., Lake B.G., Swenberg J., Wilkinson C., Williams G., van Gemert M. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA risk assessment guidelines. Regul. Toxicol. Pharmacol. 1999, 29:327-357.
20. Dunn O. Multiple comparisons using rank sums. Technometrics 1964, 6:241-252.
21. Dunnett C. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 1955, 50:1096-1121.
22. Dunnett C.W. New tables for multiple comparisons with a control. Biometrics 1964, 20:482-491.
23. Elcombe C.R., Elcombe B.M., Foster J.R., Chang S.C., Ehresman D.J., Butenhoff J.L. Evaluation of hepatic and thyroid responses in male Sprague-Dawley rats for up to eight-four days following seven days of dietary exposure to potassium perfluorooctanesulfonate. Toxicology 2012, 293:30-40.
24. Eriksen K.T., Sorensen M., McLaughlin J.K., Lipworth L., Tjonneland A., Overvad K., Raaschou-Nielsen O. Perfluorooctanoate and perfluorooctanesulfonate plasma levels and risk of cancer in the general danish population. J. Natl. Cancer Inst. 2009, 101:605-609.
25. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 1992, 119:493-501.
26. Giesy J.P., Kannan K. Global distribution of perfluorooctane sulfonate in wildlife. Environ. Sci. Technol. 2001, 35:1339-1342.
27. Gonzalez F.J., Shah Y.M. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 2008, 246:2-8.
28. Greaves P. Chapter 9: Liver and Pancreas. pg 446. Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation 2012, Academic Press, Elsevier B.V., London, Waltham, MA, San Diego, CA. fourth ed.
29. Hansen K.J., Clemen L.A., Ellefson M.E., Johnson H.O. Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. Environ. Sci. Technol. 2001, 35:766-770.
30. Hirose Y., Nagahori H., Yamada T., Deguchi Y., Tomigahara Y., Nishioka K., Uwagawa S., Kawamura S., Isobe N., Lake B.G., Okuno Y. Comparison of the effects of the synthetic pyrethroid metofluthrin and phenobarbital on CYP2B form induction and replicative DNA synthesis in cultured rat and human hepatocytes. Toxicology 2009, 258:64-69.
31. Huang W., Zhang J., Washington M., Liu J., Parant J.M., Lozano G., Moore D.D. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol. Endocrinol. 2005, 19:1646-1653.
32. IARC, 2001. IARC monographs on the evaluation of carcinogenic risks to humans. Some thyrotropic agents, vol. 79, IARC Press, Lyon.
33. Klaassen C.D., Hood A.M. Effects of microsomal enzyme inducers on thyroid follicular cell proliferation and thyroid hormone metabolism. Toxicol. Pathol. 2001, 29:34-40.
34. Klaunig J.E., Babich M.A., Baetcke K.P., Cook J.C., Corton J.C., David R.M., DeLuca J.G., Lai D.Y., McKee R.H., Peters J.M., Roberts R.A., Fenner-Crisp P.A. PPAR alpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 2003, 33:655-780.
35. Lake B.G. Species differences in the hepatic effects of inducers of CYP2B and CYP4A subfamily forms: relationship to rodent liver tumour formation. Xenobiotica 2009, 39:582-596.
36. Lau C., Anitole K., Hodes C., Lai D., Pfahles-Hutchens A., Seed J. Perfluoroalkyl acids. a review of monitoring and toxicological findings. Toxcol. Sci. 2007, 99:366-394.
37. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., Gonzalez F.J. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell Biol. 1995, 15:3012-3022.
38. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
39. Martin J.W., Mabury S.A., Solomon K.R., Muir D.C. Bioconcentration and tissue distribution of perfluorinated acids in rainbow trout (Oncorhynchus mykiss). Environ. Toxicol. Chem. 2003, 22:196-204.
40. Martin J.W., Mabury S.A., Solomon K.R., Muir D.C. Dietary accumulation of perfluorinated acids in juvenile rainbow trout (Oncorhynchus mykiss). Environ. Toxicol. Chem. 2003, 22:189-195.
41. Martin M.T., Brennan R.J., Hu W., Ayanoglu E., Lau C., Ren H., Wood C.R., Corton J.C., Kavlock R.J., Dix D.J. Toxicogenomic study of triazole fungicides and perfluoroalkyl acids in rat livers predicts toxicity and categorizes chemicals based on mechanisms of toxicity. Toxicol. Sci. 2007, 97:595-613.
42. McClain R.M. Mechanistic considerations for the relevance of animal data on thyroid neoplasia to human risk assessment. Mutat. Res. 1995, 333:131-142.
43. Morimura K., Cheung C., Ward J.M., Reddy J.K., Gonzalez F.J. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 2006, 27:1074-1080.
44. Nakamura T., Ito Y., Yanagiba Y., Ramdhan D.H., Kono Y., Naito H., Hayashi Y., Li Y., Aoyama T., Gonzalez F.J., Nakajima T. Microgram-order ammonium perfluorooctanoate may activate mouse peroxisome proliferator-activated receptorα, but not human PPARα. Toxicology 2009, 265:27-33.
45. Ohnhaus E.E., Burgi H., Burger A., Studer H. The effect of antipyrine, phenobarbitol and rifampicin on thyroid hormone metabolism in man. Eur. J. Clin. Invest. 1981, 11:381-387.
46. Olsen J.H., Boice J.D., Jensen J.P., Fraumeni J.F. Cancer among epileptic patients exposed to anticonvulsant drugs. J. Natl. Cancer Inst. 1989, 81:803-808.
47. Olsen J.H., Schulgen G., Boice J.D., Whysner J., Travis L.B., Williams G.M., Johnson F.B., McGee J.O. Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. Cancer Res. 1995, 55:294-297.
48. Omura T., Sato R. A new cytochrome in liver microsomes. J. Biol. Chem. 1962, 237:1375-1376.
49. Parzefall W., Erber E., Sedivy R., Schulte-Hermann R. Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat liver tumor promoters. Cancer Res. 1991, 51:1143-1147.
50. Pieterman E., van den Hoek A.M., Havekes L.M., Ehresman D., Chang S., Butenhoff J.L., Princen H.M., Cohen L.H. Perfluorohexanesulfonate and perfluorooctanesulfonate decrease plasma cholesterol and triglycerides in APOE*3Leiden transgenic mice. Indication for a PPARα agonist mechanism. Atherosclerosis 2007, 8(Suppl.):41.
51. Qatanani M., Zhang J., Moore D.D. Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism. Endocrinology 2005, 146:995-1002.
52. Ren H., Vallanat B., Nelson D.M., Yeung L.W.Y., Guruge K.S., Lam P.K.S., Lehman-McKeeman L.D., Corton J.C. Evidence for the involvement of xenobiotic-responsive nuclear receptors in transcriptional effects upon perfluoroalkyl acid exposure in diverse species. Reprod. Toxicol. 2009, 27:266-277.
53. Renner R. Growing concern over perfluorinated chemicals. Environ. Sci. Technol. 2001, 35:154A-160A.
54. Rosen M.B., Schmid J.E., Das K.P., Wood C.R., Zehr R.D., Lau C. Gene expression profiling in the liver and lung of perfluorooctane sulfonate-exposed mouse fetuses: comparison to changes induced by exposure to perfluorooctanoic acid. Reprod. Toxicol. 2009, 27:278-288.
55. Rosen M.B., Schmid J.E., Corton J.C., Zehr R.D., Das K.P., Lau C. Gene expression profiling in wild-type and PPAAα-null mice exposed to perfluorooctane sulfonate reveals PPARα-independent effects. PPAR Res. 2010, 2010:1-23.
56. Ross J., Plummer S.M., Rode A., Scheer N., Bower C.C., Vogel O., Henderson C.J., Wolf C.R., Elcombe C.R. Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. Toxicol. Sci. 2010, 116:452466.
57. Scheer N., Ross J., Rode A., Zevnik B., Niehaves S., Faust N., Wolf C.R. A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J. Clin. Invest. 2008, 118:3228-3239.
58. Seacat A.M., Thomford P.J., Hansen K.J., Clemen L.A., Eldridge S.R., Elcombe C.R., Butenhoff J.L. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 2003, 183:117-131.
59. Shah Y.M., Morimura K., Yang Q., Tanabe T., Takagi M., Gonzalez F.J. Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol. Cell Biol. 2007, 27:4238-4247.
60. Shipley J.M., Hurst C.H., Tanaka S.S., DeRoos F.L., Butenhoff J.L., Seacat A.M., Waxman D.J. trans-activation of PPARalpha and induction of PPARalpha target genes by perfluorooctane-based chemicals. Toxicol. Sci. 2004, 80:151-160.
61. Snedecor G.W., Cochran W.G. One Way Classifications: Analysis of Variance. Statistical Methods 1980, The Iowa State University Press, Ames, IA, USA. seventh ed.
62. Sohlenius A.K., Eriksson A.M., Hogstrom C., Kimland M., DePierre J.W. Perfluorooctane sulfonic acid is a potent inducer of peroxisomal fatty acid beta-oxidation and other activities known to be affected by peroxisome proliferators in mouse liver. Pharmacol. Toxicol. 1993, 72:90-93.
63. Sokal R., Rohlf F. Kruskal-Wallis test. Biometry 1969, W.H. Freeman and Co., San Francisco, CA, USA, pp. 388-389.
64. Sokal R.R., Rohlf F.J. Bartlett's test of homogeneity of variances. Biometry 1969, W.H. Freeman and Co., San Francisco, CA, USA, pp. 370-371.
65. Takacs M.L., Abbott B.D. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol. Sci. 2007, 95:108-117.
66. Vanden Heuvel J.P., Thompson J.T., Frame S.R., Gillies P.J. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-α, -β, and -γ, liver X receptor-β, and retinoid X receptor-α. Toxicol. Sci. 2006, 92:476-489.
67. Vansell N.R., Klaassen C.D. Effect of microsomal enzyme inducers on the biliary excretion of triiodothyronine (T(3)) and its metabolites. Toxicol. Sci. 2002, 65:184-191.
68. Vansell N.R., Klaassen C.D. Increase in rat liver UDP-glucuronosyltransferase mRNA by microsomal enzyme inducers that enhance thyroid hormone glucuronidation. Drug Metab. Dispos. 2002, 30:240-246.
69. Viollon-Abadie C., Lassere D., Debruyne E., Nicod L., Carmichael N., Richert L. Phenobarbital, beta-naphthoflavone, clofibrate, and pregnenolone-16alpha-carbonitrile do not affect hepatic thyroid hormone UDP-glucuronosyl transferase activity, and thyroid gland function in mice. Toxicol. Appl. Pharmacol. 1999, 155:1-12.
70. Waxman D.J. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 1999, 369:11-23.
71. Wei P., Zhang J., Egan-Hafley M., Liang S., Moore D.D. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000, 407:920-923.
72. Whysner J., Ross P.M., Williams G.M. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther. 1996, 71:153-191.
73. Wieneke N., Neuschafer-Rube F., Bode L.M., Kuna M., Andres J., Carnevali L.C., Hirsch-Ernst K.I., Puschel G.P. Synergistic acceleration of thyroid hormone degradation by phenobarbital and the PPAR alpha agonist WY14643 in rat hepatocytes. Toxicol. Appl. Pharmacol. 2009, 240:99-107.
74. Wijsman J.H., Van Dierendonck J.H., Keijzer R., van de Velde C.J., Cornelisse C.J. Immunoreactivity of proliferating cell nuclear antigen compared with bromodeoxyuridine incorporation in normal and neoplastic rat tissue. J. Pathol. 1992, 168:75-83.
75. Wolf C.J., Takacs M.L., Schmid J.E., Lau C., Abbott B.D. Activation of mouse and human peroxisome proliferator-activated receptor alpha by perfluoroalkyl acids of different functional groups and chain lengths. Toxicol. Sci. 2008, 106:162-171.
76. Wong H., Lehman-McKeeman L.D., Grubb M.F., Grossman S.J., Bhaskaran V.M., Solon E.G., Shen H.S., Gerson R.J., Car B.D., Zhao B., Gemzik B. Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats. Toxicol. Sci. 2005, 84:232-242.
77. Yamamoto Y., Moore R., Goldsworthy T.L., Negishi M., Maronpot R.R. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res 2004, 64:7197-7200.
78. Yu W.G., Liu W., Jin Y.H. Effects of perfluorooctane sulfonate on rat thyroid hormone biosynthesis and metabolism. Env. Tox. Chem. 2009, 28:990-996.
79. Yu W.G., Liu W., Liu L., Jin Y.H. Perfluorooctane sulfonate increased hepatic expression of OAPT2 and MRP2 in rats. Arch. Toxicol. 2011, 85:613-621.